跳转至内容
Merck
CN
  • Development and validation of reversed phase high performance liquid chromatographic method for determination of moxonidine in the presence of its impurities.

Development and validation of reversed phase high performance liquid chromatographic method for determination of moxonidine in the presence of its impurities.

Journal of pharmaceutical and biomedical analysis (2011-11-11)
Svetlana Milovanović, Biljana Otašević, Mira Zečević, Ljiljana Zivanović, Ana Protić
摘要

A simple, rapid, isocratic reversed-phase high-performance liquid chromatographic method was developed and validated for the analysis of moxonidine and its impurities in tablet formulations. The chromatographic separation was achieved on a Symmetry shield C18 column (250 mm × 4.6 mm, 5 μm) by employing a mobile phase consisting of methanol-potassium phosphate buffer (0.05 M) mixture (15:85, v/v) (pH 3.5) at a flow rate of 1 ml min⁻¹; detection at 255 nm. Central composite design technique and response surface method were used to evaluate the effects of variations of selected factors (buffer pH value, column temperature, methanol content) in order to achieve the best isocratic separation within short analysis time (less than 10 min), as well as for robustness test considerations. The method fulfilled the validation criteria: specificity, linearity, accuracy, precision, limit of detection and limit of quantitation. The method was successfully applied for the analysis of commercial moxonidine tablets.

材料
产品编号
品牌
产品描述

Moxonidine, European Pharmacopoeia (EP) Reference Standard